SPECIAL OFFER FROM SIRIUS oct2015

By : October 16, 2015

SPECIAL OFFER FROM SIRIUS-BIOTECH

Valid until: December 31th, 2015

Antibodies to B-Fibronectin, a marker of angiogenesis.

B-FN is accumulated around neovasculature during angiogenic processes  and thereby provides one of the best marker for angiogenesis and it is a component of the ECM of the niche of stem cells.

Monoclonal antibodies BC-1 and C6: 1mg 600 Euro

Send your orders at : info@sirius-biotech.com

oct2015

 

Human glioblastoma        vascular structures    stained with antibodies  to B-FN (a). A zoom view  is shown in (c). In (b),  normal brain stained  with antibodies to B-FN.


The monoclonals BC-1 and C6 recognize the fibronectin isoform containing the extra domain B (ED-B). The figure above shows the staining of vascular structure of a human glioblastoma while normal human brain sections are completely negative. In cultured transformed cells and in malignancies, the splicing pattern of FN pre-mRNA is altered, leading to an increased expression of FN isoforms containing the domains regulated by alternative splicing. In particular, the ED-B containing fibronectin isoform (B-FN), which, with some very rare exceptions, is undetectable in normal adult tissues, exhibits a much greater expression in fetal and tumor tissues, as well as during wound healing.

 

B-Fibronectin References:

  • Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon.
    Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE.
    EMBO J. 1987;6:2337-42.
  • A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors.
    Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG.
    J Cell Biol.1989 ;108:1139-48.
  • The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.
    Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L.
    Int J Cancer. 1994;59:612-8.
  • Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues.
    Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L.
    Int J Cancer. 1994 ;59:11-6.
  • Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.
    Kosmehl H, Berndt A, Katenkamp D.
    Virchows Arch. 1996 ; 429:311-22.
  • Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.
    Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L.
    Am J Pathol. 2002 ;161:1695-700.
  • Tumour vascular targeting.
    Neri D, Bicknell R.
    Nat Rev Cancer. 2005; 5:436-46.
  • Fibronectin as target for tumor therapy.
    Kaspar M, Zardi L, Neri D.
    Int J Cancer. 2006 15;118:1331-9.
  • Positron emission tomography tracers for imaging angiogenesis.
    Haubner R, Beer AJ, Wang H, Chen X.
    Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S86-103.
  • A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis- associated extra type III domain B.
    Balza E, Sassi F, Ventura E, Parodi A, Fossati S, Blalock W, Carnemolla B, Castellani P, Zardi L, Borsi L.
    Int J Cancer. 2009; 125:751-758.
  • Differentiation between high and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.
    Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L.
    Am J Pathol. 2002; 161(5):1695-700.

Filed Under: News, Uncategorized

Leave a Reply